In cancer research and therapy development, trace endotoxins can quietly compromise results. From CAR-T and T cell therapies to monoclonal antibodies, ADCs, and bispecific antibodies, these approaches all rely on high-quality recombinant proteins.
During preclinical studies, such as animal models for toxicity or cytokine profiling, the presence of endotoxins (LPS) can also compromise results and safety. As a result, ensuring endotoxin-free recombinant proteins is essential for both reliable research data and the successful development of next-generation cancer therapeutics.
Invisible Interference
Endotoxin contamination can compromise antibody generation in animal models. Even low levels could alter immune responses, reducing antibody specificity, consistency, and overall quality. At the experimental level, endotoxin-contaminated recombinant proteins can alter cellular behaviour through immune stimulatory and cytotoxic effects.
In animal studies, endotoxin-induced systemic inflammation may further compromise outcomes, potentially delaying the study or leading to termination.
In cell-based studies, endotoxin contamination can be a hidden disruptor, particularly in assays that are highly sensitive to LPS. Immune cells such as dendritic cells, macrophages, monocytes, and T cells can respond strongly to trace amounts of endotoxin, leading to cytokine release, altered proliferation, or unexpected activation. These effects can produce misleading or non-reproducible results.
The demand for endotoxin-free reagents is also critical in the development of cancer vaccines. As these therapies rely on precise modulation of the immune system, any LPS contamination can trigger unintended immune activation, mask the true efficacy of the vaccine candidate, and introduce safety risks. As a result, using endotoxin-free proteins is vital for accurately evaluating immunogenicity and supporting safe clinical translation.
Sino Biological’s ProPure Solution
While pharmacopeial guidelines provide general limits for endotoxin, immunology and translational oncology studies often require stricter control. Sino Biological’s ProPure™ endotoxin-free recombinant proteins can eliminate this variable at the source, supporting reliable results from early discovery through IND-enabling studies. Produced at the Centre for Bioprocessing (C4B) in Texas, ProPure reagents are rigorously controlled to achieve levels as low as 0.05EU/mg, with select products reaching 0.01EU/mg.
By incorporating endotoxin-free proteins, researchers in cancer therapy and cancer vaccine development can achieve consistent and accurate results in critical applications, including:
- Animal immunisation for antibody generation – ensuring high-quality antibodies and predictable host immune responses.
- Preclinical toxicology and pharmacokinetics (PK) – minimising confounding immune activation in animal models.
- In vitro cell proliferation and differentiation assays – reducing false positives caused by LPS-sensitive cells such as dendritic cells, macrophages, and T cells.
- Precise detection and quantification of cytokines – supporting reliable immunological readouts and biomarker analyses.
How ProPure Achieves Ultra-Low Endotoxin Levels
ProPure quality is not achieved solely through end-stage cleanup; C4B employs an integrated Prevention-Isolation-Detection strategy across the entire production lifecycle.
- Prevention at the source: Endotoxin-free plasmids and buffers, low endotoxin-binding plastics, and stringent CIP procedures minimise LPS introduction from cloning through purification.
- Environmental isolation: An E. coli-free production system eliminates a major source of endotoxin introduction.
- Dual detection: Each batch is tested using both LAL and/or recombinant Factor C (rFc) assays for sensitive, redundant detection and fully traceable batch data.
This end-to-end design enables ProPure proteins to arrive ready for use in demanding oncology and immunology applications, without requiring researchers to add extra purification steps that could damage protein quality or delay timelines.
With advanced technologies and rigorous quality control, Sino Biological provides endotoxin-free proteins to meet the requirements of highly sensitive research and translational applications. ProPure proteins allow researchers to reduce variability, improve reproducibility, and accelerate the development of next-generation cancer therapies.
